Xtant Medical

News

Xtant Medical to announce Fourth Quarter and Full Year 2016 Results on March 9th, 2017

BELGRADE, Mont., March 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016, after the close of the financial markets on Thursday, March 9, 2017. An accompanying conference call will be conducted by Carl O'Connell, Chief Executive Officer and President, and John Gandolfo, Chie…
Read more

Xtant Medical Announces Appointment of Carl O’Connell to Permanent CEO

BELGRADE, Mont., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as the permanent CEO, effective February 17th, 2017. Mr. O'Connell previously served as president of Xtant since October of 2016 and was appointed as interim CEO on January 21st, 2017. Prior to joining Xtant Medical, Mr. O'Connell most recently served as the Vice P…
Read more

Xtant Medical CEO Dan Goldberger announces resignation

BELGRADE, Mont., Jan. 23, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that on January 21, 2017, Dan Goldberger resigned as Chief Executive Officer and as a Director of the Company and its subsidiaries to pursue other interests. Current President Carl O’Connell will serve as interim CEO while the Company’s Board of Directors cont…
Read more

XTNT Announces Issuance of PIK Notes

BELGRADE, Mont., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the issuance of new convertible promissory notes on January 17, 2017 (the “New Notes”) to ROS Acquisition Offshore LP (“ROS”) and OrbiMed Royalty Opportunities II, LP (“OrbiMed”) for the following interest pay…

Read more

XTNT Announces closing of Registered Direct Offering

BELGRADE, Mont., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced the closing of a registered direct offering conducted without an underwriter or placement agent (the "Offering").  The Offering closed on January 17, 2017 and was with certain holders of its convertible promissory notes (“…

Read more

XTNT Announces Registered Direct Offering

BELGRADE, Mont., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced that it has entered into an agreement with certain holders of its convertible promissory notes (“Indenture Notes”) to purchase shares of Xtant's common stock in a registered direct offering conducted without an underwriter or p…

Read more

XTNT Announces Preliminary Fourth Quarter and Full Year 2016 Revenue & Adjusted EBITDA

  • Record Fourth Quarter 2016 Revenue is estimated to be at least $24.5 million which represents 10.0% year on year growth
  • Full Year 2016 Revenue is estimated to be at least $90.0 million which represents 4.1% year on year growth
  • Fourth Quarter 2016 Adjusted EBITDA* is estimated to be at least $1.25 million versus a loss of $350,000 in the Fourth Quarter of 2015
  • Full Year 2016 Adjusted EBITDA* is estimated to be at least $2.2 million versus a pro f…
Read more

Xtant Medical sponsored in the Donate Life Float at the Rose Parade in Pasadena, California

January 2, 2017: XTANT Medical proudly sponsored the Donate Life Float, themed “Teammates in Life”, in the 2017 Tournament of Roses.  Our sponsorship provides an opportunity to give back to our donor families, to support and give thanks to our recovery partners and Donate Life America, and is part of a national effort to share the life-giving message that organ, eye, and tissue donation saves and heals lives.

The 2017 Pasadena Tournament of Roses theme,…
Read more

FDA Clearance for the Xsert™ Lumbar Expandable Interbody System

Belgrade, MT, November 22, 2016 – Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Xsert Lumbar Expandable Interbody System.

The Xsert System is an all titanium expandable interbody device that expands in-situ. It is available in various sizes and lordotic angulations to fit the most complex anatom…
Read more

Xtant Medical Closes Rights Offering for Gross Proceeds of $3.8 Million

BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a subscription price of $0.75 per unit, for aggregate gross proceeds to the Company of approximately $3.8 million.

Pursuant to the Rights Offering, Xtant sold an aggr…
Read more

Xtant Medical Announces Expiration of Rights Offerings and Estimated Gross Proceeds of $3.8 Million

BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscription period for its previously announced rights offering (the "Offering") of units at a subscription price of $0.75 per unit expired on November 14, 2016, and these rights are no longer exercisable.

Based on the r…
Read more